A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors
NCT ID: NCT00038636
Last Updated: 2006-08-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
36 participants
INTERVENTIONAL
2000-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lopinavir/ritonavir
Ritonavir
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Are at least 18 years old
* Subject has not been treated for an active AIDS-defining opportunistic infection within 15 days of screening
* HIV RNA level \> 1000 copies/mL
* Previous therapy with at least one protease inhibitor, at least one non-nucleoside reverse transcriptase inhibitor and at least one nucleoside reverse transcriptase inhibitor
Exclusion:
* Subject is pregnant or breast-feeding
* Subject has received an investigational drug within 30 days prior to screening
* Have a history of pancreatitis
* History of intolerance to ritonavir
* Abnormal laboratory tests at screening
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abbott
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eugene Sun, M.D.
Role: STUDY_CHAIR
Divisional Vice President, Infectious Diseases and Virology Dept.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCSD Treatment Center
San Diego, California, United States
Johns Hopkins Hospital
Baltimore, Maryland, United States
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Hopital Pitie-Salpetriere
Paris, , France
Hospital Europeen Georges Pompidou
Paris, , France
Hospital Clinico de Barcelona
Barcelona, , Spain
Ciutat Sanitaria de Bellvitge
Barcelona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M99-049
Identifier Type: -
Identifier Source: org_study_id
NCT00006210
Identifier Type: -
Identifier Source: nct_alias